The trajectory of companies tied to Viagra's legacy presents a intricate investment landscape. While the initial boom generated substantial profits , generic competition have significantly diminished revenue. Investing in connected pharmaceutical firms now requires a careful assessment of patent safeguards, evolving healthcare shifts , and the poss